about
Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentratesAir pollution, vascular disease and thrombosis: linking clinical data and pathogenic mechanisms.Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.Antiphospholipid syndrome, adrenal failure, dilated cardiomyopathy and chronic hepatitis: an unusual manifestation of multiorgan autoimmune injury?Acquired haemophilia a in the elderly: case reports.Current and evolving features in the clinical management of haemophiliaDefinition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyHaemophilia B: from molecular diagnosis to gene therapy.A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases.Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver CirrhosisAcquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.Haemophilia A: molecular insights.Diabetes, vascular complications and antiplatelet therapy: open problems.HELLP syndrome and its relation with the antiphospholipid syndrome.Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis.Cost of care of haemophilia with inhibitors.Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.Confronting the psychological burden of haemophilia.The challenge of diagnosing pulmonary embolism in children, pregnant women, and elderly patients: a descriptive review of the literature.Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies.Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis.Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities.FEIBA versus NovoSeven in hemophilia patients with inhibitors.Noninvasive assessment of liver fibrosis in patients with chronic hepatitis C (and congenital bleeding disorders): where do we stand?Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Assessment of Hemophilic Arthropathy by Ultrasound: Where Do We Stand?Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts.Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboastheniaPerceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy.IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.Cardiovascular risk factors and outcome in patients with retinal vein occlusion.Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers.Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke.Long-lasting intestinal bleeding in an old patient with multiple mucosal vascular abnormalities and Glanzmann's thrombasthenia: 3-year pharmacological management.No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease.Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
P50
Q27026389-0BE4262F-A704-449D-9E05-685465374784Q30570388-21AE9F90-9E2B-4717-9272-6F3B786DBE3CQ33374177-11BC1F69-D55C-4760-827A-0FF5634D58EFQ33505023-27537C50-344F-4C5C-86E7-9874292C4CC5Q33699716-5A9F281E-6ECE-43B9-A03C-59EE23261C53Q33708976-E7EAADDE-04FA-44EB-AA6A-166022E389F6Q33709003-B492C673-E311-408D-889D-EEA9B941495BQ34416394-8CDCD976-F5AA-40C4-A7DF-FAC6953DCC86Q35127766-40D5A8AC-FC5F-424F-A539-47DF6516254EQ35176160-A956104B-5455-41A5-A878-B64BA7ECCD5BQ35265369-30D855DE-0615-47C3-8D76-8AE7B9552DF2Q35814151-DCDC171F-875B-485A-8D8D-7066C7C184B1Q36187384-C49DCC65-5A23-4335-A69C-48CB0F635285Q36793856-2509B69A-216C-4C14-A69B-E798CCFBFB10Q37338975-D2C3A799-53AE-485D-AF02-F92E83358A9CQ37588912-9391953B-D196-465C-B4AA-D079F1E94C55Q37602403-97195F55-A312-4F3A-9DE1-1BF4466177D6Q37618924-6F9CD61F-5E99-47E7-858A-08017B94F59DQ37767264-739D519B-7E85-4120-BE98-F947E53FC004Q37767750-24E52D3C-63EF-4677-A042-1DD61BAC03F0Q37971350-A2E33AC0-0D46-4D9A-B78F-9B98904D6E58Q37976470-F4DD7606-81E7-489C-A5D3-7E981F066D97Q37984127-348B63E4-4FBE-4514-98E1-5EA1BC609FC2Q37991557-3F71AFE3-31F1-4672-9D20-03B3E1E5CDACQ38135319-B3C0DB83-0161-458D-94F5-33D638309AB5Q38135321-57BFA066-F0E5-450E-9AF9-D7F8902865B4Q38136137-DDDDC352-84AD-48E7-9DEE-B5716EFF6EECQ38227605-F7D33EFE-884C-4AF8-8EDF-8F1984467F4DQ38819927-66498363-FFFF-49D7-A776-7824C30DAE65Q38852612-12D2E75F-A6DA-4A37-B39E-050B6D7307D1Q42139661-1E078263-4FF8-4460-9AD2-9E23B84C9B88Q42236600-B1CCC9E6-A6A3-4273-BD1F-82ADF3CC4CDEQ42991475-73EB5690-EC14-46EB-A40A-503551C18094Q43218590-241A7100-C7A9-41B4-B1E3-DD0803AA7AD2Q43286564-9AD74217-412C-44A6-9337-C640D53EDC85Q43847043-F2C5F338-8B96-425B-B956-F67D2174714EQ43847066-C38EB4E5-7E75-44D6-BC6D-BB5427BA323EQ44148290-24C48B09-C4BF-4993-A03F-7BD2B96C9251Q44318737-FDFFE99E-1367-4808-B6EC-A3EFC7FDE809Q44320698-6A7D4482-85CC-4245-9C8F-50CF95FFF7A5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Coppola
@ast
Antonio Coppola
@en
Antonio Coppola
@es
Antonio Coppola
@nl
type
label
Antonio Coppola
@ast
Antonio Coppola
@en
Antonio Coppola
@es
Antonio Coppola
@nl
prefLabel
Antonio Coppola
@ast
Antonio Coppola
@en
Antonio Coppola
@es
Antonio Coppola
@nl
P106
P1153
7103251282
P21
P31
P496
0000-0003-3697-706X